Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 55

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 55
---
 There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of
the Right to Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy.

At the state level, legislatures have increasingly
passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities
and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will
be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors
and governmental authorities in reference pricing systems and publication of discounts and list prices.

There have been, and likely will continue to be,
legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare.
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain
profitability, or commercialize our product. Such reforms could have an adverse effect on anticipated revenue from product candidates
that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability
to develop product candidates. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government,
insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or
impose price controls may adversely affect:

  the demand for our product candidates, if approved;  

  our ability to receive or set a price that we believe is fair for our products;  

  our ability to generate revenue and achieve or maintain profitability;  
  the amount of taxes that we are required to pay; and                    
  the availability of capital.                                            

We expect that the other healthcare reform measures
that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage
criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any
denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction
in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize
our product candidates